Related coverage linked through entity extraction aliases.
Feb 27, 2026
Eli Lilly's oral GLP-1 drug orforglipron showed superior blood sugar control and weight loss compared to oral semaglutide in a year-long trial of over 1,500 patients with type 2 diabetes.
Feb 25, 2026
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
Feb 24, 2026
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Feb 24, 2026
Novo Nordisk's experimental triple-action obesity drug UBT251 achieved up to 19.7% weight loss in a Phase 2 trial in China, as the company works to regain ground against rival Eli Lilly in the obesity drug market.
Feb 20, 2026
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Feb 26, 2026
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Feb 26, 2026
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
Feb 26, 2026
Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion on February 9, 2026, gaining access to proprietary circular RNA technology and an "in vivo" CAR-T platform for immunology and oncology applications.
Feb 25, 2026
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
Feb 25, 2026
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Feb 24, 2026
Novo Nordisk and China's United Biotechnology reported that experimental obesity drug UBT251 led to mean weight loss of up to 19.7% in a midstage clinical trial in China, expanding Novo's obesity pipeline.
Feb 24, 2026
Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, causing Novo shares to fall 15% and raising questions about its competitive position.
Feb 24, 2026
Eli Lilly reported Q4 2025 EPS of $7.54 versus $6.67 expected and projected 2026 revenue of $80-83 billion. Mounjaro revenue surged 110% to $7.4B while Zepbound jumped 123% to $4.2B in Q4.
Feb 24, 2026
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
Feb 23, 2026
Novo Nordisk's experimental weight loss drug CagriSema achieved 23% weight loss after 84 weeks compared to 25.5% with Eli Lilly's tirzepatide in a head-to-head Phase 3 trial, sending Novo shares down 15% in Copenhagen.
Feb 20, 2026
Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, sending Novo shares down 15% and erasing over $400 billion in market value since 2024.
Feb 18, 2026
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
Feb 18, 2026
Artificial intelligence is transforming pharmaceutical industry employment by creating hybrid roles and in-house AI teams rather than causing widespread job losses, with drug discovery emerging as the primary area for AI talent demand.
Feb 17, 2026
Novo Nordisk sues telehealth companies over compounded weight-loss drugs as employers explore AI-based alternatives to costly GLP-1 medications. About 1 in 8 Americans now take GLP-1 drugs for weight loss or diabetes.
Feb 17, 2026
Novo Nordisk secured FDA approval for oral Wegovy tablets in December 2025 and subsequently sued telehealth company Hims & Hers for patent infringement over compounded versions. The company is the only manufacturer with an FDA-approved GLP-1 weight loss pill.
